Claude

Know the Business

Centene is the nation's largest Medicaid managed care company and largest Marketplace (ACA exchange) insurer, processing nearly $195 billion in revenue by intermediating between government payers and healthcare providers for 28 million predominantly low-income Americans. The business generates razor-thin margins – typically 1-3% pre-tax – on enormous premium throughput, and its value comes down to one thing: whether it can keep its health benefits ratio (HBR) a few hundred basis points below the premium rate states and CMS set. The market is most likely underestimating the regulatory risk from the OBBBA's Medicaid eligibility tightening and the expiration of enhanced Marketplace subsidies, while overestimating the permanence of the 2025 HBR blowout.

How This Business Actually Works

Centene collects per-member-per-month premiums from state Medicaid agencies, CMS (Medicare/PDP), and subsidized individuals (Marketplace), then pays out medical claims to hospitals, physicians, and pharmacies. The difference between premiums collected and claims paid is gross margin – and the entire economic engine pivots on a single ratio: the HBR.

The cost structure is almost entirely variable – medical claims (~92% of premium revenue in 2025) plus SG&A (~7.4%). There is no significant fixed-cost leverage. Incremental profit comes from three sources: (1) negotiating rate increases from states that exceed medical cost trend, (2) managing utilization through care management and network design, and (3) earning risk adjustment transfers by coding member acuity more completely than competitors.

The 360 bps HBR deterioration from 2024 to 2025 wiped out more than $6 billion in gross margin. The SG&A ratio improved, but SG&A savings are pennies compared to the dollars at stake in medical cost management.

How revenue flows: States set capitated rates based on actuarial analysis of population acuity. Centene has limited pricing power – it cannot raise prices unilaterally. It must either (a) lobby states for adequate rate increases, (b) manage costs below the rate, or (c) exit unprofitable contracts. In Marketplace, Centene files rates annually with state regulators and took corrective pricing actions on 95% of its Marketplace membership for 2026.

Capital allocation: The business generates strong operating cash flow when HBR is controlled ($5.1 billion in 2025, $8.1 billion in 2023). Centene has spent aggressively on buybacks ($3.0 billion in 2024, $0.4 billion in 2025) and carries $15.5 billion in senior notes. The $6.7 billion goodwill impairment in Q3 2025 pushed debt-to-capital to 46.5%.

The Playing Field

Centene competes in government-sponsored managed care, where five companies control the vast majority of Medicaid managed care enrollment nationally.

What the peer set reveals:

Centene trades at the lowest price-to-sales multiple of any major MCO (~0.09x), reflecting the market's verdict that its revenue is lower quality – pass-through premium with minimal margin. UnitedHealth earns more operating income from its Optum services platform than Centene earns in total revenue from its most profitable segments. Elevance has the Blue Cross brand moat and a growing Carelon services business. Humana is a pure Medicare Advantage play that struggled with its own HBR blowout.

Molina is the closest comp: pure-play Medicaid/Marketplace, similar HBR challenges (91.7% in 2025), but at $45 billion in revenue it is one-quarter of Centene's size, yet carries a similar market cap per dollar of adjusted earnings. Molina's G&A ratio (6.6%) beats Centene's (7.4%), suggesting the scale advantage Centene should theoretically enjoy has not materialized in admin efficiency.

Centene's real competitive advantage is incumbency: it holds contracts in 30 states and has 40% Medicaid managed care market share nationally. Winning new state contracts requires years of relationship-building, local subsidiary infrastructure, and demonstrated performance on quality metrics. But incumbency is not a moat against rate inadequacy – if states do not raise rates enough, Centene must absorb the loss or exit.

Is This Business Cyclical?

Managed Medicaid is acyclical in the traditional economic sense – enrollment tends to increase during recessions as more people qualify for Medicaid. But Centene faces a different kind of cycle: the regulatory cycle.

The cycle that matters here is political, not economic:

2020-2023: Pandemic expansion. The PHE continuous enrollment requirement added 3.6 million Medicaid members to Centene's rolls. Revenue surged from $111 billion (FY2021) to $154 billion (FY2023).

2023-2025: Redetermination unwind. States began removing ineligible members, driving Medicaid enrollment down from ~15 million to 12.5 million. Many of these members shifted to Marketplace, where Centene also leads – Marketplace membership grew from 3.9 million to 5.5 million.

2025-2027: OBBBA regulatory tightening. The One Big Beautiful Bill Act introduces work requirements for Medicaid expansion members, more frequent redeterminations, and cost-sharing – all expected to reduce enrollment starting 2027. Simultaneously, enhanced Marketplace subsidies expired at the end of 2025, expected to shrink 2026 Marketplace enrollment.

The medical cost cycle also matters. In 2025, accelerated utilization – behavioral health, home health, high-cost drugs – drove the HBR to 91.9%. Every MCO in the peer set experienced similar pressure. The lag between cost increases and state rate adjustments is typically 12-18 months, meaning 2025 pain should translate to rate relief in late 2026 and 2027.

The 19% revenue growth in 2025 is misleading – much of it is driven by the IRA's Part D benefit redesign, which dramatically increased PDP premium throughput (Medicare segment revenue up 62% YoY) without a proportional increase in profit. Revenue growth does not equal earnings growth in this business.

The Metrics That Actually Matter

HBR is the metric. Everything else is secondary. A managed care company with a sub-88% HBR is printing money. Above 91%, it is destroying value. Centene crossed that line in 2025.

Adjusted EPS matters because GAAP earnings are distorted by the $6.7 billion goodwill impairment. The adjusted figure ($2.08 in 2025 vs. $7.17 in 2024) reveals a 71% decline in underlying profitability – still severe, but a recoverable operating problem rather than a permanent capital destruction event.

Operating cash flow is the reality check. Despite the GAAP loss, Centene generated $5.1 billion in operating cash flow in 2025 (vs. just $154 million in 2024, which was distorted by PBM transition timing). The business produces cash even in bad years.

Medicaid membership is the franchise barometer. The loss of 500K Medicaid members in 2025 on top of 1.8 million in 2024 is the key structural concern. Centene is protesting contract losses in Georgia and Texas and lost the Florida CMS contract.

Star Ratings drive Medicare economics. The improvement from 23% of MA members in 3.5+ star plans (2024 ratings) to 60% (2026 ratings) is a genuine inflection that will flow into 2027 revenues.

What I'd Tell a Young Analyst

Watch three things. First, track the Medicaid rate adequacy cycle state by state – the HBR will mean-revert if states adjust rates, and Centene's corrective Marketplace pricing for 2026 should help the Commercial segment, but the timing and magnitude of Medicaid rate increases is the swing factor for 2026-2027 earnings.

Second, model the OBBBA membership impact carefully. Work requirements and more frequent redeterminations could remove 2-4 million members from Medicaid expansion programs nationally starting 2027. Centene, with 40% market share, takes a disproportionate hit. But the remaining population will be sicker (higher acuity), which means higher per-member revenue if rates adjust properly.

Third, do not confuse revenue scale with competitive advantage. Centene is the largest Medicaid MCO, but it does not earn higher margins than Molina at one-quarter the size. The real advantages are incumbency in 30 states, the D-SNP positioning for dual-eligible integration by 2030, and the breadth of the Marketplace footprint. The real risk is that the company is too big and too dependent on government program design choices it cannot control. If you had to pick one number to forecast for the next three years, make it the Medicaid HBR – everything else follows from that.